CHI gathers information through the organization of scientific conferences, publication of market reports, and compilation of industry deals. We would like to share some of the information we have gathered with you. The following articles offer insight into the genomics industry. We hope you find this information useful.

Click on the title of the article to see the full text.  Click here to go back to the current articles page

Articles from Issue 25, December 2002:

• The Life Science Industry Represents Unique Opportunities for Informatics Companies: An Interview with Shiv Tasker of Blackstone Computing
• Pharmacogenetics Offers New Opportunities in Disease Treatment and How Medicines Are Marketed: An Interview with Craig Fitzgerald of HealthCarta

Articles from Issue 24, November 2002:

• Robust Growth Expected in the Monoclonal Antibodies Marketplace: Gayle Mills of Abgenix Discusses Factors Driving Antibody Technology
• New Regulatory Requirements Are Changing the Way Pharmaceutical Companies Do Business and Creating a New Market for Informatics Systems: An Interview with Bernard P. Wess, Jr., of PERSEID

Articles from Issue 23, October 2002:

• Research Efforts in Pursuit of Genomic Signatures of Toxicity: CuraGen-A Case Study
• Companies Using "In Silico Biology"-Computer Modeling of Cells, Pathways, and Networks: An Interview with Colin Hill and Iya Khalil of Gene Network Sciences

Articles from Issue 22, September 2002:

• High-Content Screening: Approaches, Applications, and Challenges
• A CDR-Based Approach for Generating Fully Human Antibodies: A Commentary from Carl Borrebaeck of BioInvent

Articles from Issue 21, August 2002:

• A Potential New High-Throughput Tool for Screening for Molecular Interactions: An Interview with Michael Famulok of the University of Bonn
• Proteomewide Chips: Not So Fast? 

Articles from Issue 20, July 2002:

• The Importance of mRNAs and Alternative Splicing in Microarrays: An Interview with Alon Amit of Compugen
• Haplotyping and Other Key Approaches for Pharmacogenomics: A Commentary from J. Claiborne Stephens of Genaissance Pharmaceuticals

Articles from Issue 19, June 2002:

• Microscopy Advances for High-Content Screening: An Interview with Edward Hunter of Q3DM
• Building Better Predictive Models for ADMET: An Interview with Ken Korzekwa of ArQule

Articles from Issue 18, May 2002:

• Data a Key Driver for Toxicogenomic Studies
• Better Testing for Realizing the Promise of Pharmacogenomics: A Commentary from Michael P. Murphy of Gentris

Articles from Issue 17, April 2002:

• Genomic Tools Provide Unique Insights into Toxicology: An Interview with Jeffrey Voss of the Abbott Bioresearch Center
• Better Understanding of Diseases and Drug Targets Through Systems Biology: An Interview with N. Stephen Ober of Beyond Genomics

Articles from Issue 16, March 2002:

• Translating Human Genomics for Health Care Providers and Consumers
• Trends and Challenges in Gene Expression Data Collection and Analysis: Commentary from Gene Logic

Articles from Issue 15, February 2002:

• Reducing the Investment Made in Likely Drug Development Failures
• Protein Localization Studies Provide Key Insights into Protein Function

Articles from Issue 14, January 2002:

• High-throughput Genomics: Throughput Advances Drive Platform Integration
• Haplotyping—A Key Approach to Studying Genetic Variation

Articles from Issue 13, December 2001:

• Genomics-Based Drug Discovery and Development Companies: Great Risks, Great Potential Rewards
• A Novel High-Throughput Genotyping Technology: An Interview with P. Scott White of the Center for Human Genome Studies

Articles from Issue 12, November 2001:

• Commercial Opportunities from Applied Genomics
• Linux clusters -The New Workhorse of Gene Sequencing, Proteomics and Drug Development

Article from Issue 8, July 2001:

• Successful Acquisition Integration- An Engineering Giant’s Perspective

Articles from Issue 7, June 2001:

• Protein Arrays: Promising Tools for Large-Scale Protein Studies
• Application of Structural Pharmacogenomics to Clinical Testing and Pharmaceutical Research

Article from Issue 6, May 2001:

• Structural Proteomics: The Upstream and Downstream Benefits of Protein Structure Information

Articles from Issue 5, April 2001:

• How the Genomics Revolution Affects FDA Regulation
• Moving up a dimension: Proteomics Dealmaking

Article from Issue 4, February 2001:

• Structural Genomics Emerges as a Dynamic Commercial Field

Articles from Issue 3, January 2001:

• The Current State of Proteomic Technology
• 2000: A Banner Year For Genomic Dealmaking

Article from Issue 2, December 2000:

• Gene Expression Analysis: Solid Tools, Real Results

Articles from Issue 1, October 2000:

• The Leading Genomic Dealmakers: Strategies and Technological Platforms
• Genomic Deal Highlights, September 2000

New articles will be announced in CHI's Genome Link newsletter each month and then posted on this page. If you do not currently receive our e-cast newsletter, click here to sign up.